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Abstract
Background: In a non-inferiority (NI) trial, analysis based on the intention-to-treat (ITT) principle is anti-conservative,
so current guidelines recommend analysing on a per-protocol (PP) population in addition. However, PP analysis
relies on the often implausible assumption of no confounders. Randomisation-based efficacy estimators (RBEEs)
allow for treatment non-adherence while maintaining a comparison of randomised groups. Fischer et al. have
developed an approach for estimating RBEEs in randomised trials with two active treatments, a common feature of
NI trials. The aim of this paper was to demonstrate the use of RBEEs in NI trials using this approach, and to appraise
the feasibility of these estimators as the primary analysis in NI trials.
Methods: Two NI trials were used. One comparing two different dosing regimens for the maintenance of remission
in people with ulcerative colitis (CODA), and the other comparing an orally administered treatment to an
intravenously administered treatment in preventing skeletal-related events in patients with bone metastases from
breast cancer (ZICE). Variables that predicted adherence in each of the trial arms, and were also independent of
outcome, were sought in each of the studies. Structural mean models (SMMs) were fitted that conditioned on
these variables, and the point estimates and confidence intervals compared to that found in the corresponding ITT
and PP analyses.
Results: In the CODA study, no variables were found that differentially predicted treatment adherence while
remaining independent of outcome. The SMM, using standard methodology, moved the point estimate closer to 0
(no difference between arms) compared to the ITT and PP analyses, but the confidence interval was still within the
NI margin, indicating that the conclusions drawn would remain the same. In the ZICE study, cognitive functioning
as measured by the corresponding domain of the QLQ-C30, and use of chemotherapy at baseline were both
differentially associated with adherence while remaining independent of outcome. However, while the SMM again
moved the point estimate closer to 0, the confidence interval was wide, overlapping with any NI margin that could
be justified.
Conclusion: Deriving RBEEs in NI trials with two active treatments can provide a randomisation-respecting estimate
of treatment efficacy that accounts for treatment adherence, is straightforward to implement, but requires thorough
planning during the design stage of the study to ensure that strong baseline predictors of treatment are captured.
Extension of the approach to handle nonlinear outcome variables is also required.
Trial registration: The CODA study: ClinicalTrials.gov, identifier: NCT00708656. Registered on 8 April 2008. The ZICE
study trial: ClinicalTrials.gov, identifier: NCT00326820. Registered on 16 May 2006.
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Background
In the majority of randomised controlled trials (RCTs),
the primary goal is to investigate the superiority of one
treatment over another [1]. However, in some instances,
it can be sufficient to demonstrate that a treatment is no
worse than another on some outcome of interest. This is
particularly true where a standard treatment is already
in place (a so-called ‘active control’), and the new treat-
ment could offer substantial benefits on non-primary
outcomes such as reduce side effects, reduced costs,
simpler dosing regimen, etc. This is the purpose of a
non-inferiority (NI) trial, where the aim is to demon-
strate that a new treatment is no worse than a standard
treatment by more than an acceptable amount [2].
The ‘gold standard’ approach to analysis in a superior-
ity trial is based on the intention-to-treat (ITT)
principle, where participants are analysed in the groups
to which they were originally randomised [3]. This ap-
proach is favoured as it preserves randomisation and, in
the case of departures from randomised treatment,
makes treatment groups appear more similar; therefore,
producing a conservative estimate of treatment effect.
However, in a NI trial it is desirable for treatment groups
to be as similar as possible, and therefore an ITT
analysis is viewed as anti-conservative in this situation
[4, 5]. Current recommendations are that a per-protocol
(PP) analysis should be conducted alongside an ITT ana-
lysis for NI trials [6]. A PP analysis excludes participants
with departures from randomised treatment, but as-
sumes that the group of participants who are excluded
are similar to those who are included on both observed
and unobserved variables; an assumption that is usually
deemed implausible [7]. The ideal analytical method
would be based on participants who received the treat-
ment to which they were allocated, while maintaining a
comparison of groups as randomised (and thus not
prone to the selection biases that are common with a PP
analysis).
Randomisation-based efficacy estimators (RBEEs),
such as Structural Mean Models (SMMs), compare the
effect of treatment in the group of participants who were
allocated to and adhered to treatment with the group al-
located to receive control (or standard treatment) but
who would have adhered to treatment (had they been al-
located to the treatment group) [8]. The approach allows
for treatment non-adherence [9] while maintaining a
comparison of randomised groups. Fischer et al. have
developed an approach for estimating treatment efficacy
in randomised trials with two active treatments, a com-
mon feature of NI trials [10].
The aim of this paper is to demonstrate the use of
RBEEs in NI trials using the methods outlined by
Fischer et al., and to appraise the feasibility of these
estimators as the primary analysis in NI trials. A brief
introduction to randomisation-based efficacy estima-
tors will be given in ‘Methods section’, specifically
where the estimators are used in trials with two ac-
tive interventions. This section will also highlight gen-
eral steps to fitting these models using standard
statistical software, before concluding with a descrip-
tion of the studies used as examples in this paper.
‘Results section’ will present worked examples using
data from the studies described in ‘Methods section’,
while ‘Discussion section’ will summarise the work of
the previous sections and highlight the implications
of using these methods in practice.
Methods
Traditional approaches to deriving efficacy in RCTs
An ITT analysis is used to determine treatment effect-
iveness in RCTs [11, 12]. Under certain circumstances
(e.g. all participants receive all of the treatment to which
they were randomised), an ITT analysis can also be used
to estimate treatment efficacy. However, in the presence
of non-adherence, or departures from randomised treat-
ment, the most common approach to assessing treat-
ment efficacy in an RCT is to conduct a PP analysis.
This analysis excludes participants who are determined
to have not adhered to their randomised treatment.
However, it fails to maintain a comparison of groups as
randomised, and is therefore prone to selection bias
[11]. While selection bias is thought to be minimised in
trials with blinding, and modified definitions of these
populations that adjust for observed confounders can be
used, selection bias can never be completely discounted
from any analyses that make postrandomisation exclu-
sions or manipulations.
Structural Mean Models to derive randomisation-based
efficacy estimators
By recognising that at the beginning of a trial all partici-
pants have two potential outcomes – one if they are
treated and one if they are not, a SMM relates a treated
participant’s observed outcome to their (potentially
counterfactual) outcome that would have been observed
had they received no treatment [13]. Standard ap-
proaches to fitting a SMM rely on using observed expos-
ure, treating randomisation as an instrument (i.e.
assuming that it is independent of both observed and
unobserved confounders and only effects outcome
through its effect on exposure), and finding a value of
the treatment effect such that balance is achieved be-
tween groups on the outcome in participants who were
not treated [14].
By doing this it becomes possible to derive an estimate
of treatment efficacy (the effect that receiving treatment
has on outcome) that is not prone to the usual selection
biases usually found in traditional methods (Fig. 1).
Gillespie et al. Trials  (2017) 18:117 Page 2 of 11
SMMs with two active treatments
Conventional SMM methodology is based on trials com-
paring an active treatment to no treatment (or a
placebo). However, in non-inferiority trials it is common
to just compare two active treatments – one experimen-
tal and one standard. This complicates matters, as with-
out a no-treatment group there is no observed outcome
on which to base the potential outcome in the untreated,
and therefore the method described above cannot be
readily applied.
By identifying baseline covariates that are differentially
associated with treatment adherence for each of the
treatments, the methodology developed by Fischer et al.
allows for the estimation of two distinct causal parame-
ters, from which a contrast can then be made. Identify-
ing baseline covariates that are differentially associated
with treatment adherence for each of the treatments,
but independent of outcome, allows separate sets of in-
struments to be derived for each treatment, and allows a
potential treatment-free response to be estimated [10].
If suitable baseline covariates are not identified, two
distinct causal parameters cannot be estimated. Despite
this, a linear contrast can still be made and the following
approaches can be taken:
 Fix adherence levels as the same in both arms, and
estimate the treatment efficacy in the subpopulation
that would always adhere to their treatment at that
given level
 Perform sensitivity analyses that vary adherence
parameters to explore the impact that differential
adherence levels has on outcomes
 Use standard SMM methods and consider the
standard treatment as the ‘placebo’ group. This will
allow for the comparison of average outcomes at
varying levels of the experimental treatment to the
average outcome if assigned to the standard
treatment (regardless of adherence levels to that
standard treatment)
Example studies
Two non-inferiority trials, whose data were available to
the authors, were used to illustrate the proposed
methods and its uses and limitations. Beyond the avail-
ability of data, the two studies described below were
chosen as they were both two-arm non-inferiority trials,
with two active treatments involving patients with long-
term conditions whose medication use was monitored
throughout the trial. The trials differ in terms of the na-
ture of the interventions being compared, with Colitis
Once Daily Asacol (CODA) comparing the same treat-
ment prescribed with different regimens, and Zoledronate
versus Ibandronate Comparative Evaluation (ZICE) com-
paring two different treatments with different modes of
administration. These examples, while contrasting, are
typical of the types of non-inferiority trials conducted and
will, therefore, provide useful insight into the methods
proposed.
The Colitis Once Daily Asacol (CODA) trial
The CODA trial was designed to assess the efficacy and
safety of once daily dosing (OD) versus three times daily
dosing (TDS) of mesalazine over a 12-month period for
patients in remission with ulcerative colitis. The study
concluded that the OD regimen was no worse than (non-
inferior to) the TDS regimen in terms of clinical relapse
using both an ITT and a PP analysis [15]. Research nurses
counted the number of tablets returned at each study visit,
and deducting this from the number of tablets issued de-
termined the number consumed during the study period.
Adherence to study medication in the original trial was
defined as participants consuming at least 75% of their is-
sued medication. A subset of participants also had their
medication adherence recorded using the Medication
Event Monitoring System (MEMS), an electronic monitor
that records the date and time of each bottle cap opening.
This substudy demonstrated that adherence to study
medication was generally lower and more varied for par-
ticipants allocated to the TDS regimen. However, as this
type of measure was not used for all trial participants, it
will not be considered further in this paper [16].
The Zoledronate versus Ibandronate Comparative
Evaluation (ZICE) trial
The ZICE trial was designed to assess whether orally ad-
ministered ibandronic acid (OIA) was non-inferior to
intravenously administered zoledronic acid (IZA) in pre-
venting skeletal-related events (SREs) in patients with
bone metastases from breast cancer. The study con-
cluded that orally administered ibandronic acid was in-
ferior to intravenously administered zoledronic acid in
both ITT and PP populations [17].
Adherence to study medication was noted by the treat-
ing clinician at interim and 12-weekly visits. Participants
were defined as having adhered to their allocated treat-
ment if the clinician recorded that study medication had
been administered as prescribed during all scheduled
visits. See Additional file 1 for more detail.
Fig. 1 Causal Directed Acyclic Graph (DAG) illustrating using
randomisation as an instrument to derive a randomisation-based
efficacy estimate
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Statistical methods
Outcomes
For the CODA trial, the outcome of interest was the pro-
portion of participants relapsing during the 12-month
study period. The OD regimen was considered to be non-
inferior to the TDS regimen as long as the lower bound of
the 95% confidence interval of the difference in the pro-
portion of participants in each arm relapsing (OD minus
TDS) did not include −0.1.
For the ZICE trial, the outcome of interest for this
paper was the proportion of participants experiencing a
SRE during the first 12 months of the study. This is a
simplified version of the primary outcome from the
main paper (time and frequency of SREs), and used for
illustration purposes only. There was, therefore, no pre-
specified non-inferiority margin for this outcome.
Modelling approach
Determining baseline covariates that differentially
predict adherence Deriving distinct causal estimators
for each treatment arm relied on identifying baseline
variables that predicted adherence to treatment differ-
ently in each arm, while not predicting clinical outcome.
Determining these predictors involved two main steps.
First, multivariable logistic regression was used to deter-
mine the factors that predicted clinical outcome. Vari-
ables that were identified univariably at the 20%
significance level were entered into the multivariable
model, with backward selection used to retain variables
independently associated at the 10% significance level.
Following this, multivariable logistic regression was
used, with the binary adherence variable as the outcome.
Predictors of adherence were entered one-by-one into a
regression model that included trial arm, and interaction
between candidate predictor and trial arm, and the pre-
dictors of clinical outcome that were identified during
the previous step. Any variables that were associated
with adherence at the 20% significance level, as either a
main effect or as an interaction with trial arm, were
retained in the multivariable regression model. Predic-
tors that remained associated at the 10% significance
level were then retained in the final regression model.
For the CODA trial, the candidate baseline predictors
used in the outcome and adherence models were age
(<65, ≥65 years), age at diagnosis (≤25, 26–45, 46–64,
≥65 years), gender, length of remission (<12 months,
≥12 months), calprotectin concentration (<60 mg/kg stool,
≥60 mg/kg stool), smoking status (never smoker, current
smoker, ex-smoker), employment status (unemployed,
employed), maximum documented extent of colitis
(extensive, left-sided or sigmoid, proctitis), disease
duration (≤10 years, 11 to 20 years, >20 years), num-
ber of relapses during the past 2 years (1, 2, 3, ≥4),
and endoscopy findings (normal, not normal).
For the ZICE trial, the predictors were age, gender,
Body Mass Index (BMI), the modified Brief Pain
Inventory severity score, quality of life (EORTC QLQ-
C30 score version 3.0), SRE within the previous
3 months, previous use of bisphosphonates, treatments
being received (including painkilling drugs, chemother-
apy, hormone therapy, and trastuzumab).
Variables that were included in the models were
checked for notable deviations from linearity. While the
relationship between age and outcome in the CODA
trial was considered non-linear, this was not the case for
the ZICE trial. A cut-off of 65 years was chosen to distin-
guish between elderly/non-elderly participants (see http://
www.who.int/healthinfo/survey/ageingdefnolder/en/).
Fitting the structural mean model The SMM models
were fitted using a two-stage, least squares, instrumental
variables regression approach. Using this procedure, the
trial arm (the instrument), predictors of outcome, and dif-
ferential predictors of adherence were used to estimate
values of the adherence variables in the first stage. These
values were then regressed onto the outcome in the sec-
ond stage. These regressions were fitted simultaneously in
order to avoid standard errors that were artificially large.
The Huber-White robust standard error, with additional
correction for small samples, was used in order to make
correct inferences about the differences in proportions
[18]. Table 1 provides sample syntax using Stata (v13.0).
Table 1 Sample Stata (v13.0) syntax of the structural mean
models described in ‘Methods section’ and fitted in ‘Results
section’
The Colitis Once Daily Asacol (CODA) trial
ivregress 2sls < <Outcome> > (<<Adherence indicator> > = < <Trial arm
indicator>>), vce(robust)
The Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
ivregress 2sls < <Outcome> > <<Predictors of outcome> > <<Predictors
of adherence> > (<<Adherence in experimental arm> > <<Adherence in
standard treatment arm> > = < <Trial arm indicator> > <<Predictors of
outcome> > <<Trial arm * Predictors of outcome interactions> >
<<Predictors of adherence> > <<Trial arm * Predictors of adherence
interaction>>), vce(robust)
lincom[<<Experimental treatment arm effect> > - < <Standard treatment
arm effect>>]
For the CODA trial, the adherence indicator was one variable that was
1 if the participant was allocated to the OD arm (experimental
intervention) and adhered, 0 if they were allocated to the OD arm and
did not adhere, and also 0 if they were allocated to the TDS arm
(standard care).
For the ZICE trial, as distinct causal parameters were identifiable, each
arm had its own variable to denote adherence. This variable was 1 if
the participant was allocated to the arm and adhered, 0 if they were
allocated to the arm and did not adhere, and 0 if they were allocated to
the other arm.
OD once daily, TDS three times daily
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Results
The CODA trial
The analysis is based on 188 randomised participants
with outcome data. In total, 174 participants adhered to
their study medication (92.6%), with these making up
the PP population (Fig. 2). The percentage of partici-
pants adhering to study medication was higher in those
randomised to the intervention arm compared to the ac-
tive control arm (95.7% and 89.4%, respectively).
Overall, 56 participants relapsed within the 12-month
follow-up period (29.8% of all participants). The percent-
age of participants who relapsed was lower in the inter-
vention arm compared to the active control arm (24.5%
and 35.1%, respectively). The main trial analysis based
on complete cases demonstrated that the relapse rate
was 10.6 percentage points higher in those randomised
to the TDS arm compared to in the OD (95% confidence
interval (CI): −2.5 to 23.8 percentage points). As the
lower limit of the 95% CI did not include −10%, and this
was also confirmed in the PP analysis, the findings con-
firmed the non-inferiority of the OD regimen compared
to the TDS regimen.
Predictors of outcome
Predictors of relapse were age (participants aged 65 years
or older had decreased odds of relapsing during the
follow-up period), length of remission (participants in
remission for at least 12 months had decreased odds of
relapsing during the follow-up period), and endoscopy
findings at baseline (participants with non-normal en-
doscopy findings at baseline had increased odds of re-
lapsing during the follow-up period) (Table 2).
Predictors of adherence
When conditioning on the above variables, smoking sta-
tus at baseline was the only variable that remained inde-
pendently associated with participants adhering to their
study medication at the 10% significance level (Table 3).
Compared to non-smokers, the odds of participants ad-
hering to their study medication was higher in those
who were ex-smokers. However, smoking status did not
differentially predict adherence across the two arms (i.e.
the interaction between smoking status and trial arm
was not statistically significant).
Structural mean model
It was not possible to derive two distinct causal parame-
ters based on observed data, as there were no baseline
variables differentially associated with adherence for
each of the arms. Given that the definition of adherence
was binary, the only sensible analysis was to consider the
standard treatment (active control) as the ‘placebo’
group and use standard SMM methods.
Fig. 2 Flow diagram describing data available for each type of analysis in the Colitis Once Daily Asacol (CODA) trial
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The SMM analysis found that after adjusting for ad-
herence, the relapse rate was 11.1 percentage points
higher in those randomised to intervention. The 95% CI
did not contain −10% (95% CI −2.5 to 24.7 percentage
points), and non-inferiority could be confirmed based on
this analysis (Fig. 3).
The ZICE trial
The analysis is based on 1037 randomised participants
with outcome data. In total, 621 of 915 participants with
adherence data adhered to their study medication
(67.9%), with these making up the PP population. The
percentage of participants adhering to study medication
was higher in those randomised to the OIA arm com-
pared to the IZA arm (77.4% and 60.7%, respectively).
Baseline covariate data were available for 796 partici-
pants. This made up the SMM population (Fig. 4).
Overall, 382 participants experienced an SRE within
the 12-month follow-up period (36.8% of all partici-
pants). The percentage of participants who experienced
an SRE was higher in the OIA arm compared to the IZA
arm (38.3% and 35.4%, respectively). The trial analysis
based on complete cases demonstrated that the SRE rate
was 3.0 percentage points higher in those randomised to
the OIA arm compared to in the IZA (95% confidence
interval (CI) −2.9 to 8.8 percentage points) and con-
cluded that OIA was inferior to IZA.
Predictors of outcome
The odds of experiencing an SRE within the first
12 months of the study were higher in participants with
higher BMI scores, in participants who had poor role
functioning, worse nausea/vomiting symptoms, had ex-
perienced an SRE in the 3 months prior to the study, or
had recently used pain medication. The odds of experi-
encing an SRE within the first 12 months of the study
were lower in women than in men, in participants with
higher overall general health, and in participants with in-
creasing dyspnoea (Table 4).
Predictors of adherence
After conditioning on the above, both cognitive func-
tioning and use of chemotherapy were independently
associated with adhering to study medication differ-
ently in the two arms (Table 5). The results from the
model suggest that the odds of adhering to study
medication are:
 Higher for participants allocated to the OIA arm,
with the lowest levels of cognitive functioning, and
not undergoing chemotherapy at baseline
 Higher as cognitive functioning increases for
participants allocated to the IZA arm
 Lower as cognitive functioning increases for
participants allocated to the OIA arm
 Higher for participants undergoing chemotherapy at
baseline and allocated to the IZA arm
 Lower for participants undergoing chemotherapy at
baseline and allocated to the OIA arm
 BMI Body Mass Index, IZA Intravenously
administered zoledronic acid, OIA Orally
administered ibandronic acid OIA, QLQ-C30
EORTC QLQ-C30 score version 3.0, SRE Skeletal-
related event,
Table 2 Multivariable determinants of outcome in the Colitis Once Daily Asacol (CODA) trial (odds of relapsing during the 12-month
follow-up period)
Variable Adjusted odds
ratio
95% Confidence interval p value
Lower Upper
Age at baseline (≥65 compared to <65 years) 0.30 0.10 0.88 0.028
Length of remission (≥12 compared to <12 months) 0.34 0.14 0.81 0.014
Endoscopy findings at baseline (non-normal compared to normal) 4.14 2.04 8.39 <0.001
Table 3 Multivariable determinants of adhering to medication in the Colitis Once Daily Asacol (CODA) trial
Purpose Variable Adjusted odds
ratio
95% Confidence
interval
p value
Lower Upper
Associated with disease status at
12 months (relapsed/still in remission)
Intervention (OD arm compared to TDS arm) 2.61 0.75 9.03 0.131
Age at baseline (≥65 years compared to <65 years) 2.42 0.27 21.70 0.430
Length of remission (≥12 months compared to <12 months) 1.05 0.29 3.75 0.940
Endoscopy findings at baseline (non-normal compared to normal) 0.31 0.10 1.01 0.053
Associated with adherence to study
medication
Smoking status at baseline (current smoker compared to non-smoker) 1.31 0.25 6.79 0.076
Smoking status at baseline (ex-smoker compared to non-smoker) 11.46 1.40 94.01
OD once daily, TDS three times daily
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Structural mean model
Distinct causal parameters could be estimated using the
ZICE data, and therefore the difference between the two
arms could be calculated. After adjusting for treatment
adherence, the proportion with SRE in the first
12 months was no different in either of the arms (differ-
ence in proportions 0.0, 95% CI −13.9 to 13.8 percentage
points). While the point estimate from the SMM was
closer to no difference, the width of the confidence
interval contains any non-inferiority margin that could
be justified (Fig. 5).
Discussion
Summary of paper
This paper investigated the use of randomisation-based
efficacy estimators in non-inferiority trials. Structural
mean models were fitted using a method proposed by
Fischer et al., where baseline variables that predicted ad-
herence differentially were sought to derive causal esti-
mators in each treatment arm. This method was applied
to two datasets from clinical trials involving patients in
remission with ulcerative colitis (CODA) and breast can-
cer with bone metastases (ZICE) using standard statis-
tical software. In the CODA trial, it was not possible to
derive distinct estimators, and standard SMM methods
were applied instead, treating the active control arm in
the same way that a placebo arm would be treated. This
analysis was consistent with the ITT and PP findings (i.e.
there was evidence to suggest that OD was not inferior
to TDS in terms of preventing relapse). In the ZICE trial
it was possible to derive distinct estimators, and when
comparing the arms the point estimate implied no dif-
ference in SRE rates between the arms, but the confi-
dence intervals were considerably wider than the ITT
and PP analyses.
Strengths and weaknesses of the approach
To our knowledge, this is the first paper to demon-
strate the potential use of randomisation-based efficacy
Fig. 3 Forest plot of the difference in relapse rates in the Colitis
Once Daily Asacol (CODA) trial for various analysis sets
Fig. 4 Flow diagram describing data available for each type of analysis in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
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Table 4 Multivariable determinants of outcome in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial (odds of
experiencing a skeletal-related event during the first 12 months)
Variable Adjusted odds
ratio
95% Confidence
interval
p value
Lower Upper
Gender (female compared to male) 0.23 0.06 0.88 0.032
18.5 kg/m2 < BMI≤ 25 kg/m2 (normal/healthy weight) compared to≤ 18.5 kg/m2 (underweight) 6.16 0.75 50.65 <0.001
25 kg/m2 < BMI≤ 30 kg/m2 (overweight) compared to≤ 18.5 kg/m2 (underweight) 6.85 0.84 56.13
30 kg/m2 < BMI≤ 35 kg/m2 (moderately obese) compared to≤ 18.5 kg/m2 (underweight) 13.17 1.59 108.81
35 kg/m2 < BMI≤ 40 kg/m2 (severely obese) compared to≤ 18.5 kg/m2 (underweight) 6.99 0.81 60.39
BMI > 40 kg/m2 (very severely obese) compared to≤ 18.5 kg/m2 (underweight) 13.11 1.44 119.65
QLQ-C30 global health domain (per unit increase) 0.98 0.98 0.99 0.001
QLQ-C30 role functioning domain (per unit increase) 1.01 1.00 1.02 0.005
QLQ-C30 nausea / vomiting domain (per unit increase) 1.01 1.01 1.02 <0.001
QLQ-C30 dyspnoea domain (per unit increase) 0.99 0.99 1.00 0.056
SRE within the three months prior to baseline compared to no SRE within three months prior to baseline 1.56 1.14 2.13 0.006
Recent use of pain medication at baseline compared to no recent use of pain medication 1.63 1.08 2.46 0.019
Table 5 Multivariable determinants of adhering to medication in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial
Purpose Variable Adjusted odds
ratio
95% confidence
interval
p value
Lower Upper
Associated with the development of a
SRE within 12 months
Gender (female compared to male) 1.29 0.36 4.55 0.697
18.5 kg/m2 < BMI≤ 25 kg/m2 (normal/healthy weight) compared
to≤ 18.5 kg/m2 (underweight)
2.19 0.74 6.47 <0.001
25 kg/m2 < BMI≤ 30 kg/m2 (overweight) compared to
≤ 18.5 kg/m2 (underweight)
2.05 0.70 6.00
30 kg/m2 < BMI≤ 35 kg/m2 (moderately obese) compared to
≤ 18.5 kg/m2 (underweight)
2.35 0.79 7.03
35 kg/m2 < BMI≤ 40 kg/m2 (severely obese) compared to
≤ 18.5 kg/m2 (underweight)
3.07 0.95 9.95
BMI > 40 kg/m2 (very severely obese) compared to≤ 18.5 kg/m2
(underweight)
3.90 1.06 14.31
QLQ-C30 global health domain (per unit increase) 1.00 1.00 1.01 0.358
QLQ-C30 role functioning domain (per unit increase) 1.00 1.00 1.01 0.300
QLQ-C30 nausea/vomiting domain (per unit increase) 1.01 1.01 1.02 0.000
QLQ-C30 dyspnoea domain (per unit increase) 1.00 0.99 1.00 0.547
SRE within the 3 months prior to baseline compared to no SRE
within 3 months prior to baseline
1.07 0.79 1.46 0.660
Recent use of pain medication at baseline compared to no
recent use of pain medication
0.65 0.45 0.94 0.021
Differentially associated with adherence
by trial arm
Orally administered ibandronic acid arm (main effect) 5.77 2.05 16.26 0.001
QLQ-C30 cognitive functioning (main effect) 1.01 1.00 1.02 0.005
Orally administered ibandronic acid arm x QLQ-C30 cognitive
functioning (interaction)
0.99 0.98 1.00 0.061
Use of chemotherapy at baseline (main effect) 2.12 1.28 3.53 0.004
Orally administered ibandronic acid arm x Use of chemotherapy
at baseline (interaction)
0.47 0.22 1.02 0.057
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estimators as a primary analysis in non-inferiority trials.
Data from two non-inferiority trials were used, and the
strengths and limitations of RBEEs and SMMs using the
method proposed by Fischer et al. when applied to real-
world data were established.
Both studies captured adherence to treatment differ-
ently. In the CODA trial, adherence was captured using
tablet counts and in the ZICE trial adherence was cap-
tured using self-report and hospital attendance data.
These methods have been demonstrated to over-
estimate adherence in certain circumstances, [19–21]
but they are methods that are cheap and easy to apply in
large-scale randomised controlled trials, so are likely to
reflect the type of data obtained in other settings (as op-
posed to more direct methods or electronic monitoring).
The ZICE trial used a simplified version of the original
primary outcome in order to illustrate the use of these
methods. One consequence of this is that while a non-
inferiority margin was defined for the original primary
outcome, one was not defined for the simplified version.
While this could have limited the interpretation of this
analysis, the confidence intervals were too wide for any
NI margin to be justified, even post hoc (given that the
original trial analysis suggested inferiority, this was a
simplified outcome that would have had lower power
than a recurrent event outcome, and the confidence
interval of the SMM analysis was over twice as wide as
the ITT and PP analyses).
Both studies took adherence as a quantitative measure
and dichotomised it. While this was necessary for defin-
ing the analysis set, it was an approach that meant a loss
of information with regards to the extent to which par-
ticipants adhered to treatment. Using a binary definition
of adherence (≥75%/<75% for the CODA trial and full
versus not full for the ZICE trial) meant that the exclu-
sion restriction was less likely to be plausible [14]. How-
ever, choosing an arbitrary lower threshold would have
yielded estimates that were difficult to interpret, and
treating adherence as a quantitative measure would have
meant the additional assumption of a linear relationship
between treatment adherence and treatment effect [22].
Participants with missing outcome or adherence data
may have induced some selection bias in the findings
presented. However, adjustments for missing data (e.g.
with multiple imputation) tend to be used as secondary/
sensitivity analysis in trials [23], and the purpose of this
paper was to demonstrate the use of RBEEs as the main
analysis in NI trials. An assessment of the impact of
missing data on the interpretation of the SMM analysis
can be seen in Additional file 1. Additionally, other vari-
ables that were not recorded in sufficient detail that may
have influenced adherence to trial treatments, clinical
outcomes, and/or dropout include the use of rescue
medication and other medication that was added to a
patient’s treatment plan part way through the study.
It was also decided to present an approach that could
be adopted more readily, hence the use of modified least
squares (MLS) for a binary outcome, rather than deriv-
ing estimates using a generalised method of moments
approach [24].
Comparisons to existing trials literature
A recently published paper investigating the comparative
efficacy of two different antidepressants was the first to
demonstrate the practical implementation of the SMM
approach as outlined by Fischer et al. [25]. However, this
approach is particularly appropriate for non-inferiority
trials (as indicated in the abovementioned paper), and
thus our publication complements this work by imple-
menting this SMM approach in two non-inferiority tri-
als. One other study has reportedly implemented this
approach on a non-inferiority trial [26]. However, as this
was a placebo-controlled trial, and the paper detail of
the approach was lacking, it was unclear whether they
applied standard SMM methodology or the extended
work described by Fischer et al. Therefore, to our know-
ledge, this is the first publication to demonstrate how
this approach works in practice for non-inferiority trials
with two active interventions.
Implications for researchers
Structural mean models could replace traditional efficacy
analyses that are often reported alongside an ITT ana-
lysis in non-inferiority trials. However, this paper high-
lights the increase in variance experienced when fitting
these models, something that can only be reduced when
the models include strong predictors of adherence and
outcome. Use of the method is more accurate in terms
of reducing selection bias, but is likely to be less precise,
and increases the importance of collecting relevant and
complete baseline variables. To do this, the research
team must have a good understanding of the predictors
of outcome, and also the barriers/facilitators to adhering
Fig. 5 Forest plot of the difference in the proportion with skeletal-
related event (SRE) in the first 12 months in the Zoledronate versus
Ibandronate Comparative Evaluation (ZICE) trial for various analysis sets
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to the randomised treatments. Studies with feasibility/
pilot stages could explore these aspects, as well as how
best to capture this data, before progressing onto more
definitive studies. The significance thresholds for inclusion
of variables in this paper were higher than current prac-
tice. Future studies that collect strong baseline predictors
of adherence need not use such high significance levels.
Estimating efficacy in randomised trials is valuable, as
it answers a more patient-centred question than can be
answered by an estimate of effectiveness. That is, “what
is the effect if I take this treatment?”, rather than the
more health care professional-centred question “what is
the effect if I offer this treatment?” Both questions are
useful, but for a patient trying to understand the effect
of a treatment, the more pertinent of the two questions
relates to efficacy rather than effectiveness.
By modelling the determinants of differential adher-
ence in the different treatment arms, researchers will
also gain an understanding of the circumstances under
which the treatments will be better received by patients
and, therefore, more likely to work. For example, in the
ZICE study, we were able to demonstrate that for partic-
ipants allocated to the intravenously administered zole-
dronic acid arm, adherence was higher for patients with
higher cognitive function and for those receiving chemo-
therapy at baseline. Whereas for those allocated to the
orally administered ibandronic acid arm adherence was
lower for patients with lower cognitive function and for
those receiving chemotherapy at baseline. One explan-
ation for this could be that patients with low cognitive
function could have their medicines dispensed by a care
giver, which is likely to reduce forgetfulness and increase
adherence. Patients receiving chemotherapy at baseline
will be attending hospital regularly for these visits, and
the delivery of IZA often coincided with other hospital
visits for cancer therapy, thereby increasing their
chances of receiving IZA treatment. The implications of
this, regardless of the comparative efficacy of the treat-
ments themselves, could be that IZA should be offered
to those undergoing additional cancer treatments (or
any other treatments that require regular hospital visits).
OIA could be offered along with an additional interven-
tion to increase adherence (e.g. a reminder or monitor-
ing system), or in instances where patients were not in
control of their own medication dispensing (e.g. elderly
residents of nursing homes).
Potential extensions and future work
By extending this methodology to allow for different
types of outcome (e.g. binary, count, survival), this
approach could be more widely used. For example, the
primary analysis in the ZICE trial was based on an
Anderson-Gill model (survival model with recurrent
events) [27].
While not as necessary here, as a binary definition of
treatment receipt is required to define an analysis set,
methods of RBEEs that allow for non-linear relationships
between an increase in adherence and treatment effects
would be useful for capturing the complexity of some
dose-response relationships more accurately.
Finally, further work is needed in order to incorporate
necessary adjustments into sample size calculations for
the design of trials that wish to use these methods as
more than an exploratory analysis. Adjustments will
likely depend on the proportion of non-adherence, as
well as the number and strength of baseline predictors/
instruments that are likely to be identified.
Conclusions
In NI trials, RBEEs can provide a randomisation-
respecting estimate of treatment efficacy that accounts
for treatment adherence, addressing the deficiencies of
both ITT and PP analysis for this study design. For NI
trials involving two active treatments, RBEEs can also be
modelled, remain straightforward to implement using
standard statistical software, but require thorough plan-
ning during the design stage of the study to ensure that
strong baseline predictors of treatment are captured.
Additional file
Additional file 1: Data assumptions made for the ZICE trial. Descriptions
of how the adherence and outcome data were derived for the ZICE
study. Sensitivity analysis exploring the impact of missing data on the
interpretation of the SMM analysis in the ZICE trial. (DOCX 20 kb)
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